Theia ofbig endothelin 1 (bET) and endotmwlin 1 (ET-1) by suboelar fractions from hu polymorphonuclear leukocytes (PMNs) was investigated by bioasy and reversed-p hse igh-perfo ce liquid chromatogaphy. More than 80% of endothelin-convertig activity was recovered from the cytosodc fraction, which in to ET-1 generated other toides from bET. The procing of bET to a1 its metabolites ET- Bioasay. Male New Zealand White rabbits (2.0-2.5 kg) were killed by intravenous injection of sodium pentobarbi-
(bET) through cleavage of the Trp2l-Val22 bond by an as yet unidentified endothelin-converting enzyme (ECE). Yanagisawa et al. (1) initially suggested that ECE was a chymotrypsin-like serine protease. It was subsequently demon- strated that N-tosyl-L-phenylalanine chloromethyl ketone, an inhibitor of chymotrypsin-like serine proteases or isatoic anhydride, an inactivator of chymotrypsin, significantly reduced the secretion of ET by bovine cultured pulmonary artery endothelial cells (3) . Indeed, chymotrypsin can generate ET-1 in addition to bET1.31 from bET (4) , and chymase, a serine protease from lung mast cells, also converts bET to ET-1 (5) . However, most of the recent studies have focused on the ECE activities of aspartic (6, 7) and neutral metalloproteases (8, 9) .
The existence of ET-metabolizing enzymes has also been demonstrated. These include a phosphoramidon (PHA)-sensitive neutral endopeptidase 24.11 purified from rat kidney (10) and a similar endopeptidase present in aortic smooth muscle cells from rat fetus (11) . Cathepsin D, which converts bET to ET-1 at acidic pH, can also degrade ET-1 by removing the C-terminal tripeptide Ile-Ile-Trp (12) . Although a physiological role for ET-1 remains to be established, elevated plasma levels of the peptide have been reported in pathological states such as acute myocardial infarction (13) , preeclampsia (14) , or endotoxic shock (15) , reflecting either an increased production or a decreased inactivation of the peptide. It is not yet known whether the increased ET-1 concentration actually contributes to the etiopathogenesis of these diseases or is simply a consequence of the underlying pathology. However, a common feature of all these disorders is the accumulation and activation of polymorphonuclear leukocytes (PMNs) within discrete sites in tbt circulation, suggesting a possible link between ET-1 formation and PMN function. Indeed, Sessa et (21) . At the end of each incubation period, 50 ,ul of the mixture was removed and 5-to 20-,ul aliquots (equivalent to 50-200 pmol of bET) of the bET or 1-2 gp1 of the ET-1 incubation mixtures were assayed for contractile activity. The remaining 250 ,l was processed and analyzed by reversed-phase HPLC (RP-HPLC) using a binary mixed linear gradient, as reported by Hecker et al. (22) . In some experiments, fractions were collected at relevant time intervals, freeze-dried, and subjected to electrospray mass spectrometry analysis.
Statistical and Data Analysis. activity (results not shown). The activation of bET by the cytosol was inhibited by coincubation with the serine protease inhibitor DCI (Table 1) or the selective elastase inhibitor ONO-5046 ( Fig. lb; Table 1 ). Interestingly, the serine protease inhibitor PMSF paradoxically potentiated the contractile response, whereas the metalloprotease inhibitor PHA did not prevent the production of vasoconstrictor activity ( Table  1) .
Metabolism of bET by PMN Cytosol. The retention time of synthetic bET on RP-HPLC was 13.2 + 0.04 min, whereas that of ET-1 was 15.5 ± 0.04 min (n = 17; Fig. la) . RP-HPLC analysis revealed that, upon incubation with the PMN cytosol >98% of bET was metabolized to several peptides, of which ET-1 (retention time, 15.5 ± 0.07 min) comprised 11.3% ± 0.5% (n = 13; Figs. la and 2). The microsomal fraction also processed bET in a manner similar to the cytosol (results not shown); however, the amount of ET-1 generated was negligible and the converting activity was therefore characterized in the cytosol. The identity of bET and ET-1 was confirmed by electrospray mass spectrometry analysis with the molecular weights of the relevant fractions being 4282 and 2492, respectively. Conversion of bET to ET-1 was maximum after 30 min of incubation with the PMN cytosol (280 ± 13 pmol; n = 13), 46% of maximum (130 + 47 pmol; n = 3) after 5 min, and 87% of maximum (244 + 34 pmol; n = 3) after 15 min. The proteolytic processing of bET to ET-1 and other peptides was prevented by the serine protease inhibitors DCI or ONO-5046 (n = 9; Fig. 2 ), whereas PMSF, while partly attenuating the formation of some bET-derived peptides, had no effect on the production of ET-1 (n = 6; Fig. 2 ). The metalloprotease inhibitor PHA had no effect on the conversion of bET to ET-1 or to any of the other products seen on HPLC (n = 6; Fig. 2 ).
Processing of bET by Human Leukocyte-Derived Serine Proteases, Elastase, or Cathepsin G. Elastase cleaved bET to (+ + +, P < 0.001 vs. cytosol), and to a lesser extent by PMSF (+, P < 0.05). Consequently, DCI or ONO-5046 inhibited the formation of ET-1 (***, P < 0.001 vs. cytosol), but PMSF or PHA had no effect. Note that in the presence of DCI no ET-1 was detected. cyt, Cytosol.
several peptides (n = 7; Fig. 3a ) and this metabolism was inhibited by DCI or ONO-5046 and to a lesser extent by PMSF (n = 4; results not shown). The fragmentation pattern of bET metabolism by elastase was similar to that observed with the PMN cytosol, but the pure enzyme generated negligible amounts of ET-1 (<l% conversion), as shown by the relative lack of contractile activity on the RbJV (Fig. 3b) . However, the selective elastase inhibitor ONO-5046 prevented the conversion of bET to ET-1 by the PMN cytosol ( Figs. 1 and 2 ), suggesting that elastase is involved in the generation of ET-1, possibly via the formation of intermediates. To test this hypothesis, elastase-treated bET was incubated with the PMN cytosol in the presence of ONO-5046, and this intervention produced a 17-fold increase in the generation of ET-1 as assessed by bioassay and RP-HPLC (Fig. 3) . The formation of ET-1 under these conditions was prevented by coincubation with DCI (Fig. 3c). bET incubated with cathepsin G, when assayed for activity, elicited small contractions of the RbJV (n = 4; results not shown). This activity was due to the formation ofa metabolite chromatographically distinct from ET-1, which was identified as bET1-31 by electrospray mass spectrometry analysis (Mr, 3628).
Inactivation and Metabolism of ET-1 by PMN Microsomes. Incubation of ET-1 with PMN microsomes virtually abolished its contractile activity (6% + 2% of control; n = 8; Fig.  4b ), implying a degradation of the peptide. Most of the ET-degrading activity was recovered from the microsomal fraction and the inactivation was prevented by DCI, PMSF, or ONO-5046 but not by PHA (n = 4; Table 2 ). RP-HPLC analysis confirmed that ET-1 was metabolized by PMN microsomes, producing a major peak (retention time, 14.3 ± 0.04 min) and several minor metabolites (n = 5; Fig. 4a ). In addition, a component of the microsomal fraction, presum- Fig. 4a ). Consequently, elastase inhibited the biological activity of ET-1 only partially (Fig. 4b) .
DISCUSSION The present investigation confirms our earlier findings that
PMNs convert bET to ET-1 and degrade ET-1 (16, 17) . The combination of the techniques of bioassay and RP-HPLC enabled us to gain further insight into the nature of ECE activity in PMNs. Moreover, the use of gradient elution, as opposed to the isocratic HPLC system used in our earlier experiments, has allowed us to visualize an entire spectrum of metabolites. Based on the fragmentation pattern observed on RP-HPLC, we found that elastase accounts for a large percentage of the bET-metabolizing potential of the PMN cytosol. However, despite the similarity between elastase and the PMN cytosol in processing bET, the amount of ET-1 generated by the synthetic enzyme was negligible. Nevertheless, the serine protease inhibitor DCI or the elastase inhibitor ONO-5046 prevented the conversion by the cytosol of bET to all its various metabolites including ET-1, indicating that a serine protease(s), most likely elastase, generates an intermediate that is subsequently cleaved by another protease(s) to yield mature ET-1. This hypothesis was confirmed when incubation of the elastase-derived metabolites of bET with the ONO-5046-treated cytosol greatly enhanced the generation of ET-1. Since DCI inhibited the formation of ET-1 under these conditions, the second step must therefore also be serine protease dependent. Thus, a serine protease cascade, initiated by elastase, accounts for ECE activity in the PMN cytosol. Despite a small but significant reduction in the formation of some bET-derived metabolites, PMSF did not prevent its conversion to ET-1, suggesting that this Most of the ET-1-degrading activity was present in the microsomal fraction, and the major metabolite formed had a retention time similar to that generated from ET-1 by elastase. This finding is at variance with our earlier data showing that degradation of 125I-labeled ET-1 by activated PMNs produced a chromatographic profile virtually indistinguishable from that seen with purified human leukocyte cathepsin G (17) . Degradation of ET-1 by the microsomal fraction, however, also appears to involve more than one enzyme, for there was no major breakdown of ET-1 by the cytosol despite the elastase-like activity present there. Moreover, elastase alone does not metabolize ET-1 effectively. Therefore, elastase may initiate the metabolism of ET-1, with further cleavage of the elastase-derived fragments by other specific or nonspecific proteases.
The formation of a biologically active metabolite (bET1_31) from bET by human leukocyte-derived cathepsin G is consistent with an earlier study showing that bET is cleaved by cathepsin G to a fragment of 27-31 amino acids, which is 5 times less potent than ET-1 as a vasoconstrictor (23) .
The metalloprotease inhibitor PHA has been reported to prevent the conversion of bET to ET-1 in vitro in cultured endothelial (9) or smooth muscle (24) cells and to reduce the pressor effects of bET in vivo (25) . PHA-sensitive endopeptidases have also been shown to possess ET-metabolizing activity (10, 11) . In the present study, PHA had (29) . The proteolytic activity of cathepsin G and elastase is controlled by the plasma inhibitors a1-antichymotrypsin and a1-antitrypsin, Pharmacology: Kaw et al.
Proc. Natl. Acad. Sci. USA 89 (1992) respectively (28, 29) . More recently, al-antitrypsin has been found colocalized with elastase in the primary granules of PMNs (30) . The presence of endogenous inhibitors makes it less likely for PMN-derived serine proteases to be involved in the physiological processing of bET or ET-1. But an inherited or acquired deficiency (28, 29) of these inhibitors can permit an unrestrained action of such enzymes. Moreover, in pathological conditions in which PMNs are activated, even in the presence of functional endogenous inhibitors, sufficiently high concentrations of these proteases can overcome the activity of inhibitors and thereby actively participate in the generation and degradation of ET-1. In this context, a recent study demonstrated an elevation of plasma ET-1 as well as elastase in a group of women suffering from pre-eclampsia (14) , suggesting a possible link between elastase and ET-1. A separate report showed that a factor from the serum of pre-eclamptic women suppressed ET-1 production in primary cultures of human umbilical vein endothelial cells (31) . The authors suggested that preeclamptic serum contains an endopeptidase responsible for the observed degradation of ET-1. As PMN activation is a feature of pre-eclampsia (32), the excessive release of serine proteases may well account for this effect.
The existence of similar correlations in other disorders associated with PMN activation may yield important information regarding their etiopathogenesis and, therefore, merit investigation.
